title: First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.
abstract: Pazopanib is a standard first-line treatment for metastatic clear-cell renal cell carcinoma (ccRCC). Very few data on its activity in non-clear-cell renal cell carcinoma (nccRCC) are currently available. The aim of this study was to retrospectively analyze efficacy and toxicity of pazopanib in nccRCC patients.
  
  
  
  Records from advanced nccRCC patients (consecutive sample) treated with first-line pazopanib between 2010 and 2015 at 17 Italian centers were reviewed. Response rate, progression-free survival (PFS), and overall survival (OS) were evaluated. Univariate and descriptive analyses were performed.
  
  
  
  Thirty-seven patients with nccRCC were treated with first-line pazopanib; 51% had papillary histology, 24% chromophobe, 22% unclassified, and 3% had Xp11.2 translocation. Dose reductions/temporary interruptions for toxicity were required in 46% of cases. Grade (G) 3/4 toxicity was seen in 32%, G1/2 in 89% of cases; 81% achieved disease control, with 10 partial responses (27%) and 20 cases of stable disease (54%); 16% of patients had disease progression as best response. Median PFS and OS were 15.9 and 17.3 months, respectively. In univariate analysis, nephrectomy (P = .020), Memorial Sloan Kettering Cancer Center (MSKCC) score (P < .001), basal neutrophil/lymphocyte ratio (NLR; P = .009) and performance status (PS) (P = .001) were associated with PFS; MSKCC score (P < .001), International Metastatic Renal Cell Carcinoma Database Consortium score (P = .003), PS (P < .0001), nephrectomy (P = .002), histology (P = .035), dose reductions/interruptions (P = .039), best response to treatment (P < .001), and NLR (P = .008) were associated with OS.
  
  
  
  In nccRCC patients, treatment with pazopanib was effective and feasible; dose reductions required for toxicity were similar as expected in ccRCC.
authors.affiliation: University Hospital of Parma, Medical Oncology, Parma, Italy.
authors.forename: Sebastiano
authors.initials: S
authors.lastname: Buti
authors.affiliation: University Hospital of Parma, Medical Oncology, Parma, Italy. Electronic address: bersamel@libero.it.
authors.forename: Melissa
authors.initials: M
authors.lastname: Bersanelli
authors.affiliation: Santa Chiara Hospital, Medical Oncology, Trento, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Maines
authors.affiliation: Fondazione Pascale National Cancer Institute, Napoli, Italy.
authors.forename: Gaetano
authors.initials: G
authors.lastname: Facchini
authors.affiliation: Sant'Orsola-Malpighi Hospital, Medical Oncology, Bologna, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Gelsomino
authors.affiliation: San Martino Hospital, Medical Oncology, Belluno, Italy.
authors.forename: Fable
authors.initials: F
authors.lastname: Zustovich
authors.affiliation: University Hospital of Ancona, Medical Oncology, Ancona, Italy.
authors.forename: Matteo
authors.initials: M
authors.lastname: Santoni
authors.affiliation: European Institute of Oncology, Milano, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Verri
authors.affiliation: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
authors.forename: Ugo
authors.initials: U
authors.lastname: De Giorgi
authors.affiliation: Arcispedale S. Maria Nuova, Medical Oncology, Reggio Emilia, Italy.
authors.forename: Cristina
authors.initials: C
authors.lastname: Masini
authors.affiliation: Casa Sollievo della Sofferenza Hospital, Medical Oncology, San Giovanni Rotondo, Italy.
authors.forename: Franco
authors.initials: F
authors.lastname: Morelli
authors.affiliation: Antonio Cardarelli Hospital, Medical Oncology, Napoli, Italy.
authors.forename: Maria Giuseppa
authors.initials: MG
authors.lastname: Vitale
authors.affiliation: Azienda Ospedaliera Universitaria Integrata of Verona, Medical Oncology, Verona, Italy.
authors.forename: Teodoro
authors.initials: T
authors.lastname: Sava
authors.affiliation: Hospital of Guastalla, Medical Oncology, Guastalla, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Prati
authors.affiliation: Ospedali Riuniti Villa Sofia-Cervello Hospital, Medical Oncology, Palermo, Italy.
authors.forename: Carmelinda
authors.initials: C
authors.lastname: Librici
authors.affiliation: Pederzoli Hospital, Medical Oncology, Peschiera, Italy.
authors.forename: Anna Paola
authors.initials: AP
authors.lastname: Fraccon
authors.affiliation: IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Medical Oncology n°1, Genova, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Fornarini
authors.affiliation: Istituto Oncologico Veneto, IOV-IRCCS, Medical Oncology 1 Unit, Padova, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Maruzzo
authors.affiliation: University Hospital of Parma, Medical Oncology, Parma, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Leonardi
authors.affiliation: Santa Chiara Hospital, Medical Oncology, Trento, Italy.
authors.forename: Orazio
authors.initials: O
authors.lastname: Caffo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007191:Indazoles; D007558:Italy; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D007191:Indazoles; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib
keywords: Chromophobe RCC; First-line treatment; Papillary RCC; Pazopanib; nccRCC